Experienced in Lynch Syndrome

Dr. Lee Ratner

Oncology
Washington University
1 Barnes Jewish Hospital Plz, 
Saint Louis, MO 
Accepting New Patients
Experienced in Lynch Syndrome
Washington University
1 Barnes Jewish Hospital Plz, 
Saint Louis, MO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Lee Ratner is an Oncologist in Saint Louis, Missouri. Dr. Ratner is rated as an Experienced provider by MediFind in the treatment of Lynch Syndrome. His top areas of expertise are Bone Tumor, Anal Cancer, Leukemia, and Non-Hodgkin Lymphoma. Dr. Ratner is currently accepting new patients.

His clinical research consists of co-authoring 96 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in MO
Hospital Affiliations
Barnes Jewish Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Cox Health
  • EPO
  • PPO
Essence Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

WASHINGTON UNIVERSITY
1 Barnes Jewish Hospital Plz, Saint Louis, MO 63110

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Multicenter Phase II Study of Pomalidomide Monotherapy in Kaposi Sarcoma
A Multicenter Phase II Study of Pomalidomide Monotherapy in Kaposi Sarcoma
Enrollment Status: Active_not_recruiting
Publish Date: October 03, 2025
Intervention Type: Procedure, Drug
Study Drug: Pomalidomide
Study Phase: Phase 2
A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors With Expansion Cohort in HIV Associated Solid Tumors and a Cohort of HIV-Associated Classical Hodgkin Lymphoma
A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors With Expansion Cohort in HIV Associated Solid Tumors and a Cohort of HIV-Associated Classical Hodgkin Lymphoma
Enrollment Status: Terminated
Publish Date: September 23, 2025
Intervention Type: Biological, Procedure
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 1
A Phase I Dose-Escalation Trial of Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab Following Cytoreduction in Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer
A Phase I Dose-Escalation Trial of Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab Following Cytoreduction in Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 17, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma
A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma
Enrollment Status: Completed
Publish Date: August 15, 2025
Intervention Type: Drug, Other
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Vinblastine
Study Phase: Phase 1/Phase 2
A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas
A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: July 18, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Filgrastim, Ibrutinib, Pegfilgrastim, Prednisone, Rituximab, Vincristine Sulfate
Study Phase: Phase 1
A Phase II Study of sEphB4-HSA in Kaposi Sarcoma
A Phase II Study of sEphB4-HSA in Kaposi Sarcoma
Enrollment Status: Completed
Publish Date: April 18, 2025
Intervention Type: Behavioral, Other, Biological
Study Drug: Recombinant EphB4-HSA Fusion Protein
Study Phase: Phase 2
Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma
Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma
Enrollment Status: Completed
Publish Date: March 14, 2025
Intervention Type: Other, Biological
Study Phase: Phase 2
A Pilot Study of Nelfinavir for the Treatment of Kaposi Sarcoma
A Pilot Study of Nelfinavir for the Treatment of Kaposi Sarcoma
Enrollment Status: Completed
Publish Date: April 30, 2024
Intervention Type: Other, Drug
Study Drug: Nelfinavir Mesylate
Study Phase: Phase 2
Tissue Acquisition for Analysis of Prognostic Factors, Immunology, and Genetic Progression of HIV-1 Associated Malignancies
Tissue Acquisition for Analysis of Prognostic Factors, Immunology, and Genetic Progression of HIV-1 Associated Malignancies
Enrollment Status: Terminated
Publish Date: March 16, 2023
Intervention Type: Other, Genetic
Phase I Trial of Cabozantinib (XL184) for Advanced Solid Tumors in Persons With HIV Infection
Phase I Trial of Cabozantinib (XL184) for Advanced Solid Tumors in Persons With HIV Infection
Enrollment Status: Completed
Publish Date: January 10, 2023
Intervention Type: Drug, Other
Study Drug: Cabozantinib S-malate
Study Phase: Phase 1
Pilot Study of Hepatic Arterial Infusion Therapy in Patients With Unresectable or Borderline Resectable Intrahepatic Cholangiocarcinoma
Pilot Study of Hepatic Arterial Infusion Therapy in Patients With Unresectable or Borderline Resectable Intrahepatic Cholangiocarcinoma
Enrollment Status: Terminated
Publish Date: August 10, 2022
Intervention Type: Drug
Study Phase: Phase 1
View 10 Less Clinical Trials

96 Total Publications

Corrigendum to "The SMAC mimetic RMT5265.2HCL induces apoptosis in EBV and HTLV-I associated lymphoma cells by inhibiting XIAP and promoting the mitochondrial release of cytochrome C and SMAC" [Leuk. Res., 36(2011) 784-90].
Corrigendum to "The SMAC mimetic RMT5265.2HCL induces apoptosis in EBV and HTLV-I associated lymphoma cells by inhibiting XIAP and promoting the mitochondrial release of cytochrome C and SMAC" [Leuk. Res., 36(2011) 784-90].
Journal: Leukemia research
Published: October 11, 2025
Similar Doctors
Distinguished in Lynch Syndrome
Dr. Benjamin R. Tan
Oncology
Distinguished in Lynch Syndrome
Dr. Benjamin R. Tan
Oncology

Washington University

1 Barnes Jewish Hospital Plz, 
Saint Louis, MO 
 (0.1 miles away)
314-747-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Benjamin Tan is an Oncologist in Saint Louis, Missouri. Dr. Tan is rated as a Distinguished provider by MediFind in the treatment of Lynch Syndrome. His top areas of expertise are Cholangiocarcinoma (Bile Duct Cancer), Familial Colorectal Cancer, Colorectal Cancer, Lynch Syndrome, and Thrombectomy. Dr. Tan is currently accepting new patients.

Distinguished in Lynch Syndrome
Dr. Rama Suresh
Hematology | Oncology
Distinguished in Lynch Syndrome
Dr. Rama Suresh
Hematology | Oncology

Washington University

10 Barnes W Dr, 200 Asthma And Allergy Cente, 
St Louis, MO 
 (11.2 miles away)
314-996-8670
Languages Spoken:
English
See accepted insurances

Rama Suresh is a Hematologist and an Oncologist in St Louis, Missouri. Dr. Suresh is rated as a Distinguished provider by MediFind in the treatment of Lynch Syndrome. Her top areas of expertise are Pancreatic Cancer, Breast Cancer, Colorectal Cancer, and Familial Pancreatic Cancer.

Distinguished in Lynch Syndrome
Dr. John L. Visconti
Oncology | Hematology
Distinguished in Lynch Syndrome
Dr. John L. Visconti
Oncology | Hematology

Washington University

5201 Mid America Plz, 
Saint Louis, MO 
 (40.8 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

John Visconti is an Oncologist and a Hematologist in Saint Louis, Missouri. Dr. Visconti is rated as a Distinguished provider by MediFind in the treatment of Lynch Syndrome. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Paget Disease of the Breast, and Familial Colorectal Cancer. Dr. Visconti is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ratner's expertise for a condition
ConditionClose
      View All 21 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile